Quantifying treatment burden: the patient burden score a study of 758 patients across three clinical urologic scenarios - Scorecard - MDSpire

Quantifying treatment burden: the patient burden score a study of 758 patients across three clinical urologic scenarios

  • By

  • Ofer N. Gofrit

  • S. Nahum Goldberg

  • Amitay Lorber

  • Mordechai Duvdevani

  • Marc Wygoda

  • Guy Hidas

  • Vladimir Yutkin

  • Liat Appelbaum Pikarsky

  • November 27, 2024

  • 0 min

Share

Clinical Scorecard: Assessing Treatment Burden: An Analysis of the Patient Burden Score in 758 Individuals Across Three Urological Clinical Scenarios

At a Glance

CategoryDetail
ConditionUrological conditions including small renal masses, muscle-invasive bladder cancer, and upper ureteral stones ≤ 10 mm
Key MechanismsMeasurement of treatment burden combining expected burdens, unexpected complications, and need for ancillary procedures
Target PopulationPatients with small renal masses (T1a, N0, M0), muscle-invasive bladder cancer (T2-4a, N0, M0), and upper ureteral stones ≤ 10 mm
Care SettingTertiary care center with multidisciplinary clinical management

Key Highlights

  • Treatment burden consists of expected burdens, unexpected downsides (complications), and need for ancillary procedures.
  • Existing scales like the modified Clavien system assess only complication severity, omitting expected burdens and ancillary procedures.
  • A novel Patient Burden Score was developed to integrate all three burden components to aid treatment decision-making.

Guideline-Based Recommendations

Diagnosis

  • Use imaging studies to assess tumor recurrence and stone-free status post-treatment.
  • Assess comorbidities using the Charlson Comorbidity Index.

Management

  • Small renal masses: percutaneous ablation or laparoscopic robot-assisted partial nephrectomy based on patient-physician discretion.
  • Muscle-invasive bladder cancer: neoadjuvant chemotherapy followed by radical cystectomy or trimodal therapy (maximal TUR followed by chemoradiation).
  • Upper ureteral stones ≤ 10 mm: ureteroscopy or extracorporeal shockwave lithotripsy.

Monitoring & Follow-up

  • Follow-up imaging at 3, 6, 12 months and annually for small renal masses.
  • Monitor for complications and treatment success in all urological conditions with minimum six months follow-up.
  • Stone-free status assessed one month after ureteral stone treatment.

Risks

  • Consider risks of hospitalization, anesthesia, surgery, pain management, and potential mutilation.
  • Monitor for postoperative complications such as bleeding, infection, and thromboembolic events.
  • Account for the possibility of needing ancillary procedures if initial treatment fails.

Patient & Prescribing Data

758 patients treated for small renal masses, muscle-invasive bladder cancer, and upper ureteral stones at a tertiary center

Treatment modality selection was individualized; the Patient Burden Score provides a quantitative measure of treatment burden to complement success rates in decision-making.

Clinical Best Practices

  • Incorporate comprehensive burden assessment including expected, unexpected, and ancillary procedure burdens when counseling patients.
  • Use multidisciplinary input to assign weights reflecting patient treatment burden.
  • Apply the Patient Burden Score alongside clinical outcomes to guide personalized treatment choices.

References

Original Source(s)

Related Content